Cambridge-based Idera Pharmaceuticals Inc. reported its lead drug candidate, for moderate to severe plaque psoriasis, was more effective than a placebo in a Phase 2a clinical trial. Idera said 48 percent of patients with the condition (12 of 25) treated with IMO-3100 demonstrated improvement. The trial involved two dose levels of the drug administered for four weeks, with a four-week follow-up. None of the 12 patients who got placebos showed significant improvement.
Idera surges on positive drug-test results
December 20, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢